VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Ide-cel CAR T-cell therapy for R/R myeloma in KarMMa-3

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the prospective Phase III KarMMa-3 study (NCT03651128) of idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory (R/R) multiple myeloma. Patients with 2-4 prior lines of therapy will be randomized 2:1 to ide-cel or a standard regimen chosen based on the patient’s most recent line of therapy. The study will evaluate the safety and efficacy of ide-cel, with the hope to move CAR T-cells to an earlier line of treatment. Progression-free survival will be the primary endpoint. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ, Actinuum

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter